Gamitrinib TPP hexafluorophosphate is primarily used in research focused on cancer therapy. It functions as an inhibitor of heat shock protein 90 (HSP90), a molecular chaperone that plays a critical role in the stability and function of numerous oncogenic proteins. By targeting HSP90, this compound disrupts the survival mechanisms of cancer cells, leading to their apoptosis. It is particularly studied for its ability to selectively accumulate in tumor mitochondria, making it a promising candidate for addressing drug resistance in various cancers. Researchers are exploring its potential in preclinical models to evaluate its efficacy in treating malignancies such as breast cancer, prostate cancer, and glioblastoma. Its mitochondrial-targeting properties also make it a valuable tool for studying the role of HSP90 in cellular stress responses and cancer progression.